GR81758B - - Google Patents

Info

Publication number
GR81758B
GR81758B GR74104A GR840174104A GR81758B GR 81758 B GR81758 B GR 81758B GR 74104 A GR74104 A GR 74104A GR 840174104 A GR840174104 A GR 840174104A GR 81758 B GR81758 B GR 81758B
Authority
GR
Greece
Application number
GR74104A
Other languages
Greek (el)
Inventor
Takao Takaya
Masayoshi Murata
Kiyotaka Ito
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838308290A external-priority patent/GB8308290D0/en
Priority claimed from GB838315542A external-priority patent/GB8315542D0/en
Priority claimed from GB838327859A external-priority patent/GB8327859D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of GR81758B publication Critical patent/GR81758B/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR74104A 1983-03-25 1984-03-14 GR81758B (oth)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB838308290A GB8308290D0 (en) 1983-03-25 1983-03-25 Pyrimidinone derivatives
GB838315542A GB8315542D0 (en) 1983-06-07 1983-06-07 Pyrimidinone derivatives
GB838327859A GB8327859D0 (en) 1983-10-18 1983-10-18 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
GR81758B true GR81758B (oth) 1984-12-12

Family

ID=27262023

Family Applications (1)

Application Number Title Priority Date Filing Date
GR74104A GR81758B (oth) 1983-03-25 1984-03-14

Country Status (13)

Country Link
US (3) US4612376A (oth)
EP (1) EP0123402B1 (oth)
KR (1) KR840008333A (oth)
CA (1) CA1256107A (oth)
DE (1) DE3473875D1 (oth)
DK (1) DK160492C (oth)
ES (2) ES8505972A1 (oth)
FI (1) FI841128A7 (oth)
GR (1) GR81758B (oth)
HU (1) HU195195B (oth)
NO (1) NO841168L (oth)
PH (1) PH22022A (oth)
SU (2) SU1349698A3 (oth)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US4598149A (en) * 1984-03-02 1986-07-01 Merck & Co., Inc. 3-amino-2-hydroxypropyl of pyrimidin-4-one useful as antihypertensive, cardioprotective, antiarrythmic, and antianginal agents
US4649142A (en) * 1984-06-25 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
US4708958A (en) * 1986-09-24 1987-11-24 G. D. Searle & Co. 6-(imidazolyphenyl)-4-iminopyrimidinones useful as hypotensive agents
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
IT1270122B (it) * 1994-10-04 1997-04-28 Ist Superiore Sanita 6-benzil-4-ossopirimidine sostituite, processo per la loro preparazione e composizioni farmaceutiche che le contengono
KR100453097B1 (ko) * 1995-09-06 2004-12-31 코와 가부시키가이샤 피리미딘유도체
US6244121B1 (en) * 1998-03-06 2001-06-12 Applied Materials, Inc. Sensor device for non-intrusive diagnosis of a semiconductor processing system
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EA010023B1 (ru) 2003-07-14 2008-06-30 Арена Фармасьютикалз, Инк. Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
EP1924262B1 (en) * 2005-08-22 2011-11-16 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
CA2678813A1 (en) * 2007-02-20 2008-08-28 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
US20100197710A1 (en) * 2007-07-23 2010-08-05 Melior Pharmaceuticals I, Inc. Methods Of Activating IRS-1 And AKT
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2011017296A1 (en) * 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
JP6632532B2 (ja) * 2014-08-29 2020-01-22 国立大学法人 東京大学 オートタキシン阻害活性を有するピリミジノン誘導体
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN110785170B (zh) 2017-04-10 2023-03-28 梅里奥尔医药I公司 脂肪细胞的治疗
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN109053589A (zh) * 2018-09-30 2018-12-21 浙江师范大学 4-亚胺基四氢嘧啶-2-酮类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296371A (oth) * 1969-02-26 1972-11-15
AU1108070A (en) * 1969-03-06 1971-08-12 Imperial Chemical Industries Limited Pyrimidine derivatives
GB1336138A (en) * 1969-12-10 1973-11-07 Ici Ltd Process for the production of pyrimidine derivatives
US3923807A (en) * 1973-09-10 1975-12-02 Takeda Chemical Industries Ltd 6-Aminouracil derivatives
US4208366A (en) * 1978-10-31 1980-06-17 E. I. Du Pont De Nemours And Company Process for preparing a nonwoven web
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent

Also Published As

Publication number Publication date
DK160492C (da) 1991-08-26
ES8601922A1 (es) 1985-11-01
ES530916A0 (es) 1985-06-16
FI841128A0 (fi) 1984-03-21
ES8505972A1 (es) 1985-06-16
CA1256107A (en) 1989-06-20
DK166884A (da) 1984-09-26
ES538190A0 (es) 1985-11-01
EP0123402B1 (en) 1988-09-07
US4746664A (en) 1988-05-24
PH22022A (en) 1988-05-13
HU195195B (en) 1988-04-28
DE3473875D1 (en) 1988-10-13
SU1436872A3 (ru) 1988-11-07
NO841168L (no) 1984-09-26
EP0123402A3 (en) 1985-09-18
DK166884D0 (da) 1984-03-23
FI841128A7 (fi) 1984-09-26
US4612376A (en) 1986-09-16
EP0123402A2 (en) 1984-10-31
SU1349698A3 (ru) 1987-10-30
US4824851A (en) 1989-04-25
KR840008333A (ko) 1984-12-14
DK160492B (da) 1991-03-18

Similar Documents

Publication Publication Date Title
BR8407173A (oth)
GR81758B (oth)
AT378328B (oth)
FR2538865B1 (oth)
GR81665B (oth)
FR2539212B1 (oth)
FR2547960B1 (oth)
GR82189B (oth)
FR2552323B1 (oth)
GR71251B (oth)
GR71985B (oth)
AU1299683A (oth)
GR79566B (oth)
GR73293B (oth)
GR72667B (oth)
GR72215B (oth)
AU1412583A (oth)
BR6301293U (oth)
AU9008182A (oth)
GR71249B (oth)
GR71767B (oth)
BG44584A1 (oth)
BG45371A1 (oth)
BG44586A1 (oth)
BG35481A1 (oth)